Brief: Cidara Therapeutics Identified A Material Weakness In Internal Control Over Financial Reporting
16/04/2024 13:38
April 16 (Reuters) - Cidara Therapeutics Inc CDTX.O :
* CIDARA THERAPEUTICS INC - IDENTIFIED A MATERIAL WEAKNESS
IN
INTERNAL CONTROL OVER FINANCIAL REPORTING
* CIDARA THERAPEUTICS- ISSUED FINANCIAL STATEMENTS FOR FY
ENDED
DEC 31, 2021, 2022 ON FORM 10-K FOR FY ENDED DEC 31, 2022 NOT TO
BE BE RELIED ON
Source text for Eikon: ID:n0001610618-24-000035
Further company coverage: CDTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cidara Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Merck Seeks Up To $8 Billion In Us Bond Sale Tied To Cidara Deal - Bloomberg News
Merck rises after Wells Fargo upgrades stock to 'overweight'
Factbox: Major deals involving U.S. drugmakers and biotechs over the past decade